Aquestive Therapeutics, Inc. disclosed that the U.S. Food and Drug Administration issued a Complete Response Letter for Anaphylm, its sublingual film formulation of dibutepinephrine, seeking approval for the treatment of Type I allergic reactions including anaphylaxis in patients weighing at least 30 kilograms. The agency did not question the drug’s active ingredient or core clinical pharmacology but cited deficiencies related to packaging, administration, and human factors validation, placing approval on hold pending additional studies and design modifications.

Why the FDA’s focus on human factors changes the regulatory calculus for emergency-use allergy therapies

The FDA’s posture on Anaphylm also lands against the backdrop of ARS Pharmaceuticals’ EURneffy, a needle-free epinephrine nasal spray that has progressed through late-stage development with regulatory momentum built around rapid administration under stress conditions. Industry observers increasingly view EURneffy as a reference point for how the agency weighs usability risk against clinical benefit in emergency allergy treatments. Unlike sublingual films, nasal delivery leverages a familiar administration pathway that may reduce cognitive and dexterity burden during anaphylaxis, a distinction that could partially explain divergent regulatory trajectories. The contrast highlights that non-injectable epinephrine is not being evaluated as a single category, but as a spectrum of human factors risk profiles, where delivery modality, failure modes, and real-world execution may outweigh pharmacokinetic similarity in approval decisions.

The Complete Response Letter shifts the regulatory conversation away from whether non-injectable epinephrine can achieve comparable pharmacokinetics to auto-injectors and toward whether patients can reliably administer the product under extreme stress. For anaphylaxis, where minutes matter and user error can be fatal, the FDA has increasingly treated human factors not as supportive data but as a core safety determinant. Industry observers note that this places Anaphylm in a different regulatory category than chronic or clinician-administered therapies, even though it is pharmacologically well understood.

The deficiencies cited relate to difficulty opening the pouch and incorrect placement of the sublingual film, both of which could delay or compromise dosing during an emergency. In regulatory terms, this elevates packaging design and instructions for use to the same level of importance as drug exposure metrics. The implication for the broader allergy drug landscape is that convenience claims must now be proven not only in usability studies but in scenarios that realistically simulate panic, impaired motor skills, and caregiver involvement.

What this decision reveals about the limits of pharmacokinetic comparability in approval decisions

Anaphylm’s clinical program demonstrated pharmacokinetic profiles comparable to established epinephrine auto-injectors, a benchmark long viewed as the primary hurdle for alternative delivery systems. However, the FDA’s response underscores that equivalence in exposure does not offset concerns about administration reliability. Regulatory watchers suggest that this reflects a maturing stance in which comparability data are necessary but no longer sufficient when a product introduces a new use behavior.

This distinction matters because epinephrine auto-injectors, despite their drawbacks, have a well-characterized failure profile that regulators understand. Introducing a sublingual film shifts risk from mechanical deployment to user cognition and dexterity. The FDA’s insistence on additional human factors validation suggests that sponsors must now demonstrate not just average usability but robustness across worst-case scenarios, including pediatric caregivers, elderly patients, and first-time users.

How human factors validation has become a gating risk rather than a post-approval refinement

Historically, human factors deficiencies have often been addressed late in development or managed through labeling changes after approval. In the case of Anaphylm, the FDA treated these issues as pre-approval blockers, indicating a higher bar for emergency self-administration products. Clinicians tracking the field note that this aligns with broader trends in device-drug combinations, where usability failures have increasingly triggered recalls and safety communications.

The requirement for a new human factors validation study, coupled with a supportive pharmacokinetic study to assess the impact of packaging and labeling changes, adds execution risk even if timelines remain theoretically short. Conducting these studies in parallel may compress development schedules, but it also introduces operational complexity. Any signal that design changes alter absorption, tolerability, or patient behavior could reset regulatory clocks.

Why the absence of CMC and core clinical concerns does not eliminate approval uncertainty

While the Complete Response Letter did not raise chemistry, manufacturing, and controls issues or question the comparability data submitted in the New Drug Application, this does not guarantee a straightforward path to resubmission. Regulatory experience suggests that human factors studies can surface unanticipated behaviors that require iterative redesign. Each iteration increases the risk of incremental delays, particularly if modifications affect labeling claims or patient eligibility assumptions.

Industry observers emphasize that the FDA’s focus on labeling comments further complicates matters. Label language for emergency therapies carries legal and clinical weight, and even minor changes can influence training requirements, reimbursement discussions, and prescriber confidence. As a result, what appears to be a narrow deficiency set can have cascading implications across commercialization planning.

What this means for clinician adoption and real-world use if Anaphylm reaches the market

From a clinical perspective, the promise of a needle-free epinephrine option addresses a well-documented problem: underuse of epinephrine in anaphylaxis due to fear of injections, stigma, or accessibility issues. Clinicians generally support additional treatment options, particularly those that could lower psychological barriers to timely administration. However, ease of carry must be matched by ease of use under stress, a standard the FDA is now explicitly enforcing.

If approved, Anaphylm would likely require clear education strategies to ensure correct administration. Regulatory watchers suggest that adoption will depend not only on label approval but on whether professional societies and emergency care protocols view the product as equivalent or supplementary to auto-injectors. Any lingering ambiguity around administration reliability could limit uptake despite clinical need.

How the FDA’s stance may influence future non-invasive epinephrine development programs

The implications extend beyond Anaphylm. Developers pursuing nasal, oral, or alternative epinephrine delivery platforms will need to integrate human factors testing earlier and more rigorously. This includes designing studies that reflect real-world chaos rather than controlled environments. The Anaphylm decision effectively sets a precedent that human factors failures in emergency settings are unacceptable regardless of pharmacological performance.

Regulatory strategists suggest this could raise development costs and lengthen timelines for innovative allergy therapies. At the same time, it may ultimately strengthen market confidence by ensuring that approved products meet a higher standard of real-world safety. For companies with robust design and testing capabilities, this could become a competitive differentiator.

Why progress in Europe and Canada may still fail to mitigate commercial and regulatory risk from delayed U.S. approval of Anaphylm

Aquestive Therapeutics has indicated plans to pursue regulatory submissions in Europe and Canada, supported by feedback suggesting no additional clinical trials are required in those jurisdictions. While this could provide earlier market access outside the United States, global regulators often monitor FDA decisions closely, particularly for safety-critical therapies. Industry observers caution that human factors concerns raised in one major market can influence questions elsewhere, even if formal requirements differ.

Moreover, commercial success for epinephrine products remains heavily weighted toward the U.S. market, given reimbursement structures and patient volumes. Delays in U.S. approval therefore have outsized strategic impact, even if international pathways progress on schedule.

What regulators, clinicians, and industry observers will scrutinize next as Anaphylm re-enters the FDA review cycle

Attention will now center on the design and execution of the revised human factors study and whether packaging modifications meaningfully reduce error risk. Regulators will scrutinize whether the new data convincingly demonstrate reliable use across diverse patient and caregiver populations. Clinicians will watch for clarity on labeling and administration instructions that could affect real-world confidence.

From an industry standpoint, the Anaphylm case will be monitored as a bellwether for how strictly the FDA applies human factors standards to other emergency therapies. The outcome will inform not only allergy drug development but broader strategies for patient-administered treatments where failure carries immediate consequences.

  allergy therapeutics, anaphylaxis, Anaphylm, Aquestive Therapeutics Inc, dibutepinephrine, emergency drug delivery, epinephrine, FDA Complete Response Letter, human factors validation, regulatory risk